ReGen poised for funding
AIM-listed biotechnology business ReGen Therapeutics is poised for new funding after announcing bullish test results for its Colostrinin Alzheimer's treatment.
News
AIM-listed biotechnology business ReGen Therapeutics is poised for new funding after announcing bullish test results for its Colostrinin Alzheimer's treatment.
News